Meta-analysis on the effect of Alemtuzumab on renal graft rejection and survival
10.3760/cma.j.issn.0254-1785.2013.04.008
- VernacularTitle:阿来佐单抗对肾移植后急性排斥反应和移植肾存活率影响的荟萃分析
- Author:
Gang LIU
;
Minyi HE
;
Jianmin HU
;
Yongguang LIU
;
Yiou ZHANG
;
Ming ZHAO
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Graft rejection;
Alemtuzumab;
Meta analysis
- From:
Chinese Journal of Organ Transplantation
2013;(4):223-226
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of Alemtuzumab on acute rejection (AR) and graft survival after kidney transplantation.Method Published domestic and foreign literatures regarding the effects of Alemtuzumab used on acute rejection and graft survival were reviewed,and Meta analysis was employed to analyze the Results.Odds ratio (OR) and its 95％ confidence interval (95％ CI) were used as the parameters to evaluate the therapeutic effects.The statistical analyses were performed with RevMan 5.1 software.Result A total of 9 pertinent research articles were reviewed.Meta-analysis of pooled results indicated that Alemtuzumab prevented the recipients of kidney transplantation from acute rejection effectively with half year prevention of OR 0.37 and 95％ CI 0.24-0.58 (P＜0.01),one year prevention of OR 0.43 and 95 ％ CI 0.29-0.64 (P＜0.01),and two year prevention of OR 0.69 and 95％ CI 0.47-1.02 (P ＜ 0.01),respectively.It was revealed that Alemtuzumab could reduce the incidence of acute rejection by 55％ in half year,51％ in one year and 28％ in two years,respectively.No statistically significant difference in graft survival was found between Alemtuzumab group and control group (OR =1.18,95％ CI 0.76-1.85,P =0.46).No statistically significant difference in patients' survival was found between Alemtuzumab group and control group (OR =0.94,95 ％ CI 0.52-1.72,P =0.85).Conclusion Alemtuzumab may effectively prevent the recipients of kidney transplantation from acute rejection,but not obviously influence the graft and patient survival.
